Diffuse large B-cell lymphoma: trials for referral
379 open trials in the registries we read. Each row links to its registry record.
Registry data only. Frontlight does not judge whether a patient can take part: the trial team decides.
Where the open trials are
Type a city to sort by distance. The distance is worked out in your browser; the city is not sent anywhere.
379 trials shown
Phase 11 site
RecruitingUnited States
NCT07649304
AMC 120, Glofitamab Plus Chemoimmunotherapy in Newly Diagnosed HIV-Associated Large B-Cell Lymphoma (The "Glofit-RCHOP Study")
National Cancer Institute (NCI)
Registry updated 5 Nov 2026
Registry record: ClinicalTrials.govPhase 1/21 site
RecruitingUnited States
NCT03223610
Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid (ViPOR) in Relapsed/Refractory B-cell Lymphoma
National Cancer Institute (NCI)
Pre-treatment window Registry sentence: “Relapsed and/or refractory and untreated Mantle cell lymphoma (MCL)”
Registry updated 5 Nov 2026
Registry record: ClinicalTrials.govPhase 2/30 sites
Not yet recruiting
NCT07917754
A Clinical Trial of MK-1045 With Zilovertamab Vedotin in Participants With Diffuse Large B-cell Lymphoma (MK-1045-010)
Merck Sharp & Dohme LLC
Registry updated 5 Nov 2026
Registry record: ClinicalTrials.govNo phase22 sites
RecruitingChina, Hong Kong SAR China
NCT07200375
An Observational Study of Glofitamab in Chinese Adult Participants With 2L Diffuse Large B-Cell Lymphoma
Hoffmann-La Roche
Registry updated 5 Nov 2026
Registry record: ClinicalTrials.govPhase 21 site
Not yet recruitingChina
NCT07917624
Prophylactic Strategies for Mitigating Central Nervous System Relapse in Diffuse Large B-Cell Lymphoma
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Registry updated 4 Nov 2026
Registry record: ClinicalTrials.govPhase 344 sites
RecruitingAustralia, Canada, United States
NCT07188558
A Study to Investigate Ronde-cel Versus Investigator's Choice CD19 CAR T-Cell Therapy
Lyell Immunopharma, Inc.
Registry updated 4 Nov 2026
Registry record: ClinicalTrials.govPhase 145 sites
RecruitingGermany, Spain, France, United Kingdom, Italy, Japan
NCT07226843
A Study of LY4584180 in Adult Participants With Previously Treated Blood Cancers
Eli Lilly and Company
Registry updated 4 Nov 2026
Registry record: ClinicalTrials.govPhase 21 site
RecruitingUnited States
NCT03125642
Auto Stem Cell Transplant for Lymphoma Patients
Masonic Cancer Center, University of Minnesota
Registry updated 4 Nov 2026
Registry record: ClinicalTrials.govPhase 3195 sites
RecruitingAustria, Australia, Belgium, Brazil, Chile, Czechia
NCT06091865
A Study to Compare How Well Odronextamab Combined With Chemotherapy Works and How Safe it is Against Rituximab Combined With Chemotherapy, in Adult Patients With Previously Untreated Diffuse Large B-cell Lymphoma
Regeneron Pharmaceuticals
Pre-treatment window Registry sentence: “Previously untreated participants for lymphoma with documented Cluster of Differentiation 20+ (CD20+) DLBCL, as described in the protocol OR relapsed or refractory DLBCL, for whom next available standard of care therapy is not available or deemed ineligible according to the investigator (Part 1A only)”
Registry updated 4 Nov 2026
Registry record: ClinicalTrials.govPhase 2/3130 sites
RecruitingArgentina, Australia, Brazil, Canada, Chile, China
NCT05139017
A Study of Zilovertamab Vedotin (MK-2140) in Combination With Standard of Care in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (rrDLBCL) (MK-2140-003)
Merck Sharp & Dohme LLC
Registry updated 3 Nov 2026 · The registries disagree on the status
Registry record: ClinicalTrials.govPhase 113 sites
RecruitingAustralia, Canada, Spain, Italy, United States
NCT05365659
IKS03 in Patients With Advanced B Cell Non-Hodgkin Lymphomas
Iksuda Therapeutics Ltd.
Registry updated 3 Nov 2026
Registry record: ClinicalTrials.govPhase 2154 sites
RecruitingBelgium, Germany, United Kingdom, Ireland, Israel, Italy
NCT06890884
A Clinical Study of Zilovertamab Vedotin (MK-2140) Plus Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Polatuzumab Vedotin Plus R-CHP in People With Diffuse Large B-cell Lymphoma (DLBCL) (MK-2140-011/waveLINE-011)
Merck Sharp & Dohme LLC
Pre-treatment window Registry sentence: “Has received no prior treatment for their DLBCL.”
Registry updated 3 Nov 2026
Registry record: ClinicalTrials.govNo phase6 sites
RecruitingSpain, United States
NCT06323447
Pivotal Study to Validate a Novel System to Non-Invasively Detect Severe Neutropenia
Leuko Labs, Inc.
Registry updated 3 Nov 2026
Registry record: ClinicalTrials.govPhase 12 sites
Not yet recruitingItaly
NCT07906080
Study to Evaluate the Feasibility and Safety of Autologous Cytokine-Induced Killer Cells (CIK_D332) in Combination With Tafasitamab and Lenalidomide in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma
Istituto Oncologico Veneto IRCCS
Registry updated 3 Nov 2026
Registry record: ClinicalTrials.govPhase 41 site
RecruitingChina
NCT07908888
Efficacy and Safety of Polatuzumab Vedotin, Rituximab Combined With Reduced-dose Cyclophosphamide, Doxorubicin and Prednisone Regimen in the Treatment of Elderly Patients With Diffuse Large B-cell Lymphoma: A Multicenter, Single-arm, Prospective Study
The First Hospital of Jilin University
Registry updated 2 Nov 2026
Registry record: ClinicalTrials.govPhase 128 sites
RecruitingAustralia, Spain, France, Italy, Poland, United States
NCT07691606
A Study of ARC-02 in B-cell NHL
Taiho Oncology, Inc.
Registry updated 2 Nov 2026
Registry record: ClinicalTrials.govPhase 1/272 sites
RecruitingAustralia, Belgium, Brazil, Canada, Chile, Colombia
NCT06395103
Substudy 01A: Zilovertamab Vedotin in Pediatric and Young Adult Participants With Hematologic Malignancies or Solid Tumors (MK-9999-01A/LIGHTBEAM-U01)
Merck Sharp & Dohme LLC
Registry updated 30 Oct 2026
Registry record: ClinicalTrials.govPhase 286 sites
RecruitingAustralia, Canada, South Korea, United States
NCT06500273
Consolidation of First-Line MRD+ Remission With Cema-cel in Patients With LBCL
Allogene Therapeutics
Registry updated 30 Oct 2026
Registry record: ClinicalTrials.govPhase 28 sites
RecruitingUnited States
NCT06765317
A Study of Glofitamab-based Treatment in People With Diffuse Large B-cell Lymphoma
Memorial Sloan Kettering Cancer Center
Registry updated 30 Oct 2026
Registry record: ClinicalTrials.govPhase 243 sites
RecruitingBrazil, South Korea, Puerto Rico, Taiwan, United States
NCT05952024
Study of Acalabrutinib and Rituximab in Untreated Elderly and/or Frail Patients With DLBCL
AstraZeneca
Pre-treatment window Registry sentence: “No prior treatment for DLBCL”
Registry updated 30 Oct 2026
Registry record: ClinicalTrials.govNo phase6 sites
RecruitingUnited States
NCT06131801
Pharmacokinetic Study of Venetoclax Tablets Crushed and Dissolved Into a Solution
Children's Hospital Medical Center, Cincinnati
Registry updated 29 Oct 2026
Registry record: ClinicalTrials.govPhase 21 site
RecruitingLebanon
NCT07387848
Glofitamab as a Bridge to and/or Consolidation Post Autologous Stem Cell Transplant in Patients With Relapsed B Cell Lymphomas
American University of Beirut Medical Center
Registry updated 29 Oct 2026
Registry record: ClinicalTrials.govNo phase1 site
By invitation onlyUnited States
NCT03226704
Leukapheresis for CAR or Adoptive Cell Therapy Manufacturing
National Cancer Institute (NCI)
Registry updated 29 Oct 2026
Registry record: ClinicalTrials.govPhase 2104 sites
RecruitingUnited States
NCT05890352
Study Adding Drugs to Usual Treatment for Large B-Cell Lymphoma That Returned or Did Not Respond to Treatment
SWOG Cancer Research Network
Registry updated 28 Oct 2026
Registry record: ClinicalTrials.govPhase 1/26 sites
RecruitingAustralia, Israel
NCT07249905
Dose Escalation and Dose Expansion Study of MDX2003 in Patients With Different Types of Lymphoma
ModeX Therapeutics, An OPKO Health Company
Registry updated 28 Oct 2026
Registry record: ClinicalTrials.govNo phase1 site
RecruitingUnited States
NCT01137643
Tissue, Blood, and Body Fluid Sample Collection From Patients With Hematologic Cancer
UNC Lineberger Comprehensive Cancer Center
Registry updated 28 Oct 2026
Registry record: ClinicalTrials.govEarly Phase 19 sites
RecruitingUnited States
NCT04139304
A Study of Daratumumab and Dose-Adjusted EPOCH in Plasmablastic Lymphoma
AIDS Malignancy Consortium
Registry updated 28 Oct 2026
Registry record: ClinicalTrials.govPhase 237 sites
Not yet recruitingBelgium, Czechia, Denmark, Spain, Finland, Croatia
2025-524230-25-00
HOVON 168:Study on epcoritamab in frail patients with diffuse large B-Cell lymphoma (DLBCL) who have not been treated before
Hemato-Oncologie voor Volwassenen Nederland (Hovon) Stichting
Registry updated 27 Oct 2026
Registry record: EU CTISPhase 11 site
RecruitingUnited States
NCT04545762
Anti-CD19 Chimeric Antigen Receptor T Cells for Treatment of Relapsed or Refractory Non-Hodgkin Lymphoma
C. Babis Andreadis
Registry updated 26 Oct 2026
Registry record: ClinicalTrials.govPhase 1/211 sites
RecruitingUnited States
NCT06533579
Gene Therapy for CD19-Positive Hematologic Malignancies (SENTRY-CD19)
Vironexis Biotherapeutics Inc.
Registry updated 26 Oct 2026
Registry record: ClinicalTrials.gov
The same sites as a list
- China133 open trials
- United States132 open trials
- Italy34 open trials
- France26 open trials
- Spain23 open trials
- Australia20 open trials
- South Korea17 open trials
- Canada16 open trials
- Poland15 open trials
- Germany14 open trials
- United Kingdom12 open trials
- Belgium9 open trials
- Brazil8 open trials
- Israel8 open trials
- Netherlands8 open trials
- Japan7 open trials
- Taiwan7 open trials
- Greece7 open trials
- Denmark7 open trials
- Sweden7 open trials
- Czechia6 open trials
- Austria5 open trials
- Portugal5 open trials
- Switzerland5 open trials
- Chile4 open trials
- Ukraine4 open trials
- Mexico4 open trials
- New Zealand4 open trials
- Hungary4 open trials
- Romania4 open trials
- Thailand3 open trials
- Ireland3 open trials
- Argentina3 open trials
- Colombia3 open trials
- Finland3 open trials
- Croatia3 open trials
- Moldova3 open trials
- Egypt3 open trials
- Hong Kong SAR China2 open trials
- Malaysia2 open trials
- Peru2 open trials
- Guatemala2 open trials
- Puerto Rico2 open trials
- Norway2 open trials
- Lithuania2 open trials
- Russia2 open trials
- Bulgaria2 open trials
- Georgia2 open trials
- India2 open trials
- Singapore1 open trials
- Costa Rica1 open trials
- Slovakia1 open trials
- Lebanon1 open trials
- South Africa1 open trials
- Qatar1 open trials
- Saudi Arabia1 open trials
- Kuwait1 open trials
- Morocco1 open trials
- Oman1 open trials
- Iraq1 open trials
- United Arab Emirates1 open trials
- Jordan1 open trials
- Pakistan1 open trials
- Slovenia1 open trials
- Estonia1 open trials
- Serbia1 open trials
Who treats this
Institutions with trials or publications in this disease (OpenAlex, registries). Institutions only, no people.
Amsterdam UMC Location Vrije Universiteit Amsterdam
Amsterdam, Netherlands
0 trials · 29 publications · ROR
Azienda Ospedaliera Citta' della Salute e della Scienza di Torino
Turin, Italy
0 trials · 29 publications · ROR
Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia
Brescia, Italy
14 trials · 34 publications · ROR
Chinese Academy of Medical Sciences & Peking Union Medical College
Beijing, China
0 trials · 112 publications · ROR
Institut universitaire du cancer de Toulouse Oncopole
Toulouse, France
0 trials · 33 publications · ROR
Rutgers, The State University of New Jersey
New Brunswick, United States
0 trials · 32 publications · ROR
The Maria Sklodowska-Curie National Research Institute of Oncology
Warsaw, Poland
0 trials · 29 publications · ROR
The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute
Columbus, United States
2 trials · 50 publications · ROR
The University of Texas MD Anderson Cancer Center
Houston, United States
3 trials · 198 publications · ROR
The University of Texas Southwestern Medical Center
Dallas, United States
0 trials · 48 publications · ROR
Third Affiliated Hospital of Harbin Medical University
Harbin, China
10 trials · 32 publications · ROR
Tianjin Medical University Cancer Institute and Hospital
Tianjin, China
3 trials · 99 publications · ROR
Università degli Studi del Piemonte Orientale “Amedeo Avogadro”
Vercelli, Italy
0 trials · 40 publications · ROR
University of North Carolina at Chapel Hill
Chapel Hill, United States
1 trials · 58 publications · ROR
What changed in the last 7 days
Registry facts, one per line, newest first.
Status changed: Completed → Running, not recruiting
NCT06667687 · Phase 1 · Australia, Denmark, Spain, United Kingdom, Israel, Japan
Source: ClinicalTrials.govStatus changed: Completed → Running, not recruiting
NCT05688475 · Phase 1 · France, Japan, Netherlands, United States
Source: ClinicalTrials.govClosed for recruitment
NCT05578976 · Phase 3 · Austria, Australia, Belgium, Bulgaria, Brazil, Canada
Source: ClinicalTrials.govStatus changed: Completed → Running, not recruiting
NCT05512390 · Phase 1 · Australia, Canada, Spain, France, Israel, Italy
Source: ClinicalTrials.govPhase changed: Phase 1/2 → Phase 2
PD-L1 PET-imaging During CAR T-cell Therapy
NCT05404048 · Phase 2 · Netherlands
Source: ClinicalTrials.govStatus changed: Completed → Running, not recruiting
PD-L1 PET-imaging During CAR T-cell Therapy
NCT05404048 · Phase 2 · Netherlands
Source: ClinicalTrials.govPhase changed: Phase 1/2 → Phase 2
NCT05283720 · Phase 2 · China, Czechia, Germany, Denmark, Spain, France
Source: ClinicalTrials.govStatus changed: Completed → Running, not recruiting
NCT05206357 · Phase 1 · Australia, Belgium, Canada, Czechia, Germany, Spain
Source: ClinicalTrials.govStatus changed: Completed → Running, not recruiting
NCT04980222 · Phase 2 · Denmark, Spain, France, Netherlands, Poland, United States
Source: ClinicalTrials.govOpened for recruitment
Efficacy and Safety of MB-CART2019.1 vs. SoC in Lymphoma Patients
NCT04844866 · Phase 2 · Austria, Belgium, Czechia, Germany, Spain, Finland
Source: ClinicalTrials.govOpened for recruitment
DALY II USA/ MB-CART2019.1 for DLBCL
NCT04792489 · Phase 2 · Canada, Croatia, Hungary, United States
Source: ClinicalTrials.govStatus changed: Completed → Running, not recruiting
NCT04384484 · Phase 3 · Argentina, Belgium, Brazil, Canada, Switzerland, Chile
Source: ClinicalTrials.govOpened for recruitment
Prephase Treatment With Prednisone +/- Vitamin D Supplementation Followed by Immunochemotherapy
NCT04442412 · Phase 3 · Italy
Source: ClinicalTrials.govStatus changed: Completed → Running, not recruiting
Brentuximab Vedotin Plus Lenalidomide and Rituximab for the Treatment of Relapsed/Refractory DLBCL
NCT04404283 · Phase 3 · Australia, Belgium, Canada, Switzerland, Czechia, Denmark
Source: ClinicalTrials.govStatus changed: Completed → Running, not recruiting
NCT04442022 · Phase 2/3 · China, Spain, Israel, Italy, Poland, United States
Source: ClinicalTrials.govOpened for recruitment
NCT04332822 · Phase 3 · Australia, Denmark, Estonia, Finland, Italy, Norway
Source: ClinicalTrials.govPhase changed: Phase 2 → Phase 1/2
NCT03356054 · Phase 1/2 · Belgium, Spain, Netherlands
Source: ClinicalTrials.govOpened for recruitment
NCT03356054 · Phase 1/2 · Belgium, Spain, Netherlands
Source: ClinicalTrials.govStatus changed: Completed → Running, not recruiting
Selinexor (KPT-330) in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)
NCT02227251 · Phase 2 · Austria, Australia, Belgium, Bulgaria, Canada, Germany
Source: ClinicalTrials.govStatus changed: Completed → Running, not recruiting
Phase 1-2 Study of ASTX660 in Subjects With Advanced Solid Tumors and Lymphomas
NCT02503423 · Phase 1/2 · Belgium, Canada, Spain, France, United Kingdom, Hungary
Source: ClinicalTrials.govClosed for recruitment
DALY II USA/ MB-CART2019.1 for DLBCL
NCT04792489 · Phase 2 · Canada, Croatia, Hungary, United States
Source: ClinicalTrials.govClosed for recruitment
Prephase Treatment With Prednisone +/- Vitamin D Supplementation Followed by Immunochemotherapy
NCT04442412 · Phase 3 · Italy
Source: ClinicalTrials.govClosed for recruitment
NCT04332822 · Phase 3 · Australia, Denmark, Estonia, Finland, Italy, Norway
Source: ClinicalTrials.govClosed for recruitment
Efficacy and Safety of MB-CART2019.1 vs. SoC in Lymphoma Patients
NCT04844866 · Phase 2 · Austria, Belgium, Czechia, Germany, Spain, Finland
Source: ClinicalTrials.govOpened for recruitment
NCT05578976 · Phase 3 · Austria, Australia, Belgium, Bulgaria, Brazil, Canada
Source: ClinicalTrials.govClosed for recruitment
NCT03356054 · Phase 1/2 · Belgium, Spain, Netherlands
Source: ClinicalTrials.govOpened for recruitment
Pivotal Study to Validate a Novel System to Non-Invasively Detect Severe Neutropenia
NCT06323447 · No phase · Spain, United States
Source: ClinicalTrials.gov
New reviews, guidelines and randomised trials in PubMed
Systematic review
A systematic review on the possible role of microRNA-155 in cancer treatment.
Frontiers in pharmacology · PubMed
Systematic review
Child's nervous system : ChNS : official journal of the International Society for Pediatric Neurosurgery · PubMed
Results card
Trials that finished or stopped in the last 3 years, with the reason the registry gives and linked publications.
Early Phase 1Ended 6 Oct 2026
Completed28 participants
NCT03244176
Feasibility Study of Induction and Maintenance Avelumab Plus R-CHOP in Patients With Diffuse DLBCL: The AvR-CHOP Study
Phase 1Ended 4 Sept 2026
Completed27 participants
NCT05359211
NKTR-255 in Combination With CAR-T Cell Therapy for the Treatment of Relapsed or Refractory Large B-cell Lymphoma
Phase 1/2Ended 28 Aug 2026
Completed36 participants
NCT03015896
Nivolumab and Lenalidomide in Treating Patients With Relapsed or Refractory Non-Hodgkin or Hodgkin Lymphoma
Phase 2Ended 30 Jun 2026
Completed30 participants
NCT05940064
Prospective Clinical Study of ZPR Regimen in Elderly Treatment-naive Diffuse Large B-cell Lymphoma
Phase 2Ended 10 Jun 2026
Completed102 participants
2023-504832-16-00
EFFICACY AND SAFETY TRIAL OF EPCORITAMAB WITH OR WITHOUT LENALIDOMIDE AS FIRST LINE THERAPY FOR SUBJECTS WITH DIFFUSE LARGE B-CELL LYMPHOMA.
Phase 2Ended 10 Jun 2026
Completed59 participants
NCT06539195
DZD8586 in Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (TAI-SHAN9)
No phaseEnded 25 May 2026
Completed1504 participants
NCT06694779
Thrombosis in Diffuse Large B-cell Lymphoma:the PREDIC-TO (PREDICt ThrOmbosis) Study
Phase 2Ended 23 May 2026
Completed61 participants
NCT06601504
Study of HMPL-760 Plus R-GemOx Versus Placebo Plus R-GemOx in Relapsed/Refractory DLBCL
Phase 3Ended 30 Apr 2026
Completed1000 participants
NCT03274492
A Study Comparing the Efficacy and Safety of Polatuzumab Vedotin With Rituximab-Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Rituximab-Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Diffuse Large B-Cell Lymphoma
Phase 1Ended 23 Apr 2026
Completed33 participants
2024-517756-35-00
A study to learn about the study medicine called PF-08046032 in people with advanced cancers.
Phase 2Ended 21 Apr 2026
Completed140 participants
NCT05144841
A Study to Evaluate Zilovertamab Vedotin (MK-2140) for Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL) (MK-2140-004)
No phaseEnded 15 Apr 2026
Completed170 participants
NCT06026644
Health-Related Quality of Life Outcomes in Patients With Aggressive B-Cell Lymphomas Treated With CAR-T Cell Therapy in Real Life
Phase 1Ended 8 Apr 2026
Completed48 participants
NCT06254495
A safety study of PF-08046044/SGN-35C in adults with advanced cancers
Phase 1Ended 13 Feb 2026
Completed25 participants
NCT00641381
Carmustine, Etoposide, Cyclophosphamide, and Stem Cell Transplant in Treating Patients With HIV-Associated Lymphoma
Phase 3Ended 3 Feb 2026
Completed330 participants
NCT03570892
Tisagenlecleucel in Adult Patients With Aggressive B-cell Non-Hodgkin Lymphoma
No phaseEnded 23 Jan 2026
Phase 1Ended 21 Jan 2026
Completed86 participants
NCT05665530
A Study of PRT2527 as Monotherapy and in Combination With Zanubrutinib or Venetoclax in Participants With R/R Hematologic Malignancies
Phase 1Ended 19 Jan 2026
Completed36 participants
NCT04049825
A Phase 1 Trial of OPB-111077 in Combination With Bendamustine and Rituximab in Patients With r/r DLBCL
Phase 2Ended 5 Jan 2026
No phaseEnded 23 Dec 2025
Completed20 participants
NCT06031194
Pharmacogenomics Effects on High-Dose Methotrexate Clearance in Patients With Diffuse Large B-Cell Lymphoma
Phase 1/2Ended 23 Dec 2025
Completed803 participants
NCT03740529
A Study of Oral LOXO-305 in Patients With Previously Treated CLL/SLL or NHL
- Population pharmacokinetic analysis of pirtobrutinib, a non-covalent BTK inhibitor, in patients with hematological malignancies from the Phase 1/2 BRUIN study. · Cancer chemotherapy and pharmacology, 2026
- Safety and activity of pirtobrutinib in patients with relapsed or refractory Waldenström macroglobulinaemia: 5-year follow-up of the open-label, multicentre, phase 1/2 BRUIN trial. · The Lancet. Haematology, 2026
- Final Analysis of the BRUIN Phase 1/2 Study Assessing the Safety and Efficacy of Pirtobrutinib Monotherapy in Patients With MCL. · American journal of hematology, 2026
Phase 3Ended 19 Dec 2025
No phaseEnded 11 Dec 2025
Completed60 participants
NCT04696692
Single-Cell Map of Immune and Lymphoma Cells in B-cell Non-Hodgkin's Lymphoma
Phase 1Ended 24 Nov 2025
Completed35 participants
NCT02568553
Lenalidomide and Blinatumomab for the Treatment of Relapsed Non-Hodgkin Lymphoma
Phase 1Ended 5 Nov 2025
Completed50 participants
NCT03259503
Olaparib and High-Dose Chemotherapy in Treating Patients With Relapsed or Refractory Lymphomas Undergoing Stem Cell Transplant
Phase 2Ended 31 Oct 2025
Completed17 participants
NCT03210662
Pembrolizumab and External Beam Radiation Therapy in Treating Patients With Relapsed or Refractory Non-Hodgkin Lymphoma
Phase 1Ended 15 Oct 2025
Phase 1Ended 13 Oct 2025
Completed46 participants
NCT05577182
Study of INCA32459 a LAG-3 and PD-1 Bispecific Antibody in Participants With Select Advanced Malignancies
Phase 1Ended 6 Oct 2025
Completed16 participants
NCT04488354
Long-term Follow-up Study for Patients Treated With CLBR001 CAR-T
Phase 1Ended 25 Aug 2025
Completed94 participants
NCT04772989
A Study to Evaluate AB308 in Combination With AB122 in Participants With Advanced Malignancies
Phase 1Ended 21 Aug 2025
Completed200 participants
NCT02290951
Study to Investigate the Safety and Tolerability of Odronextamab in Patients With CD20+ B-Cell Malignancies
Phase 1/2Ended 7 Aug 2025
Completed188 participants
NCT03677154
Trial of Mosunetuzumab (BTCT4465A) as Consolidation Therapy in Participants With Diffuse Large B-Cell Lymphoma Following First-Line Immunochemotherapy and as Monotherapy or in Combination With Polatuzumab Vedotin in Elderly/Unfit Participants With Previously Untreated Diffuse Large B-Cell Lymphoma
Phase 1/2Ended 6 Aug 2025
Completed39 participants
2023-507498-16-00
Trial of Mosunetuzumab (BTCT4465A) as Consolidation Therapy in Participants With Diffuse Large B-Cell Lymphoma Following First-Line Immunochemotherapy and as Monotherapy or in Combination With Polatuzumab Vedotin in Elderly/ Unfit Participants With Previously Untreated Diffuse Large B-Cell Lymphoma
Phase 1/2Ended 1 Aug 2025
No phaseEnded 1 Aug 2025
Phase 1/2Ended 31 Jul 2025
Phase 3Ended Jul 2025
Completed432 participants
NCT01156259
30Gy Versus 40Gy Radiotherapy for Localized Diffuse Large B Cell Lymphoma Achieving CR After Chemotherapy
Phase 1Ended 15 Jul 2025
Completed35 participants
NCT06120504
A safety study of PF-08046045/SGN-35T in adults with advanced cancers
Phase 3Ended 29 Jun 2025
Completed423 participants
NCT04231448
Phase III Study of Tucidinostat in Combination With R-CHOP in Patients With Newly Diagnosed Double-Expressor DLBCL
Phase 2Ended 21 May 2025
Completed67 participants
NCT04703686
Treatment by a Bispecific CD3xCD20 Antibody for Relapse/Refractory Lymphomas After CAR T-cells Therapy
Phase 3Ended 14 May 2025
Completed26 participants
NCT04214444
Evaluation of Prime-boost Anti-pneumococcal Vaccination in Patients With Diffuse Large B Cell Lymphoma Treated With Rituximab
Phase 2Ended 3 May 2025
Completed62 participants
NCT04263584
Copanlisib in Combination With Rituximab and CHOP Chemotherapy in Patients With Previously Untreated DLBCL
No phaseEnded 1 May 2025
Completed76 participants
NCT07007611
The Role of Surgical Resection AND Stereotactic Radiosurgery in Primary Central Nervous System -Diffuse Large B Cell Lymphoma
Phase 1Ended 22 Apr 2025
Completed15 participants
NCT03939182
Abexinostat and Ibrutinib in Diffuse Large B-cell Lymphoma and Mantle Cell Lymphoma
Phase 2Ended 19 Apr 2025
Completed60 participants
NCT04214626
R-CHOP Combined With Lenalidomide in the First-line Treatment for Patients With Diffuse Large B Cell Lymphoma
No phaseEnded 10 Apr 2025
Completed24 participants
NCT06141772
Kinetics of Circulating Tumor DNA in Lymphoma Treated by Immuno-chemotherapy
Phase 2Ended 31 Mar 2025
Completed65 participants
NCT05068440
Treatment of CD79B Mutant Relapsed/Refractory Diffuse Large B-Cell Lymphoma With Bruton Tyrosine Kinase Inhibitor Zanubrutinib
Early Phase 1Ended 21 Mar 2025
Completed7 participants
NCT04566978
89Zr-DFO-REGN3767 in PET Scans in People With Diffuse Large B Cell Lymphoma (DLBCL)
Phase 1Ended 12 Mar 2025
Completed17 participants
NCT05075603
Relapsed/Refractory Large B-cell Lymphoma With NT-I7 Post-CD19 CAR T-cell Therapy
Phase 2Ended 11 Mar 2025
Completed128 participants
NCT06074107
Study of BEBT-908 in the Relapsed or Refractory Diffuse Large B-cell Lymphoma Subjects
Phase 1Ended 5 Mar 2025
Completed30 participants
NCT05153330
A trial in patients with blood cancer and lymphatic system cancer looking at finding the optimal dose of BMF-219
No phaseEnded 15 Jan 2025
Completed80 participants
NCT06592846
FERtility After Therapy With Intensive Lymphoma in Young Women: LNH-03 1B, LNH-03 2B, LNH-07 3B, GAINED Follow-up
No phaseEnded 31 Dec 2024
Completed53 participants
NCT01357733
Interim FDG PET/CT in Diffuse Large B Cell Lymphoma (DLBCL) Patients
Phase 2Ended 24 Dec 2024
Completed74 participants
NCT03458260
Study of Pixantrone in CD20+ Relapsed/Refractory Aggressive Non-Hodgkin Lymphoma
Phase 1Ended 2 Dec 2024
Completed111 participants
NCT03467373
A Study of Glofitamab in Combination With Rituximab or Obinutuzumab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (CHOP), or Polatuzumab Vedotin Plus Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone (CHP) in Participants With Non-Hodgkin Lymphomas or With DLBCL
No phaseEnded 1 Dec 2024
Phase 3Ended 29 Nov 2024
Completed270 participants
NCT04182204
A Study to Evaluate the Safety and Efficacy of Polatuzumab Vedotin in Combination With Rituximab, Gemcitabine and Oxaliplatin Compared to Rituximab, Gemcitabine and Oxaliplatin Alone in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma
- Polatuzumab Vedotin Plus Rituximab, Gemcitabine, and Oxaliplatin in Relapsed or Refractory Diffuse Large B-Cell Lymphoma: Results From the Phase III, Randomized POLARGO Trial. · Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2026
Phase 3Ended 25 Nov 2024
No phaseEnded 17 Nov 2024
Completed102 participants
NCT06782854
Understanding the Role of Large Extracellular Vesicles in Lymphomas and Lymphoproliferative Disorders: the "Off the Beaten Track" Liquid Biopsy
Phase 1/2Ended 12 Nov 2024
Completed38 participants
NCT03129828
Ibrutinib, Bortezomib and Rituximab-CHOP for the Treatment of Elderly Patients With CD20+ DLBCL, IPI ≥ 2
Not medical advice. fetched 6 Nov 2026